You are using an outdated browser. Please upgrade your browser to improve your experience and security.

COVID-19 Update:
Questions about Coronavirus? Click here

A Strong
Start
For Superior
Survival1,2

New
5-Year OS Data Available

VYXEOS demonstrated superior efficacy with longer overall survival and higher CR and CR+CRi rates compared to traditional chemotherapya and provided an improved opportunity for transplant1,2

Median overall survivalb (primary endpoint) of 9.6 months with VYXEOS vs 5.9 months with 7+3 (HR=0.69 [0.52, 0.90], P=0.005c).1 With median follow-up of 60 months, the improvement in OS was maintained with a stable hazard ratio.3 Rate of CR was 38% with VYXEOS vs 26% with 7+3; rate of CR+CRi was 48% with VYXEOS vs 33% with 7+3.1,2 Overall rate of HSCTd was 34% with VYXEOS vs 25% with 7+31,e

In a Phase 3, randomized, multicenter, open-label, active-controlled superiority study of VYXEOS vs 7+3 (cytarabine and daunorubicin) in 309 patients (aged 60-75) with newly-diagnosed t-AML or AML-MRC1 See full study design

See VYXEOS 5-year
estimated survival data

VYXEOS LONG-TERM OS DATA

Overall survival more than doubled at 5 years with VYXEOS (18%) vs 7+3 (8%) based on KM estimates1,3

View data

National Comprehensive Cancer Network® (NCCN®) recommendations

Liposomal daunorubicin and cytarabine (VYXEOS) is the ONLY treatment recommended by NCCN for induction in sAML patients ≥60 years4

Outpatient administration

Inpatient and outpatient administration options for appropriate patients

JazzCares

VYXEOS financial assistance and coverage

Group purchasing organization

VYXEOS is now partnering with certain group purchasing organizations

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.